EA011170B1 - Применение сирамезина в лечении злокачественных опухолей - Google Patents

Применение сирамезина в лечении злокачественных опухолей Download PDF

Info

Publication number
EA011170B1
EA011170B1 EA200600987A EA200600987A EA011170B1 EA 011170 B1 EA011170 B1 EA 011170B1 EA 200600987 A EA200600987 A EA 200600987A EA 200600987 A EA200600987 A EA 200600987A EA 011170 B1 EA011170 B1 EA 011170B1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
cells
cancer
pharmaceutically acceptable
cell
Prior art date
Application number
EA200600987A
Other languages
English (en)
Russian (ru)
Other versions
EA200600987A1 (ru
Inventor
Христиан Томсен
Марсель Ляйст
Марья Яттела
Мария Стампе Андерсен
Original Assignee
Х. Лундбекк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Х. Лундбекк А/С filed Critical Х. Лундбекк А/С
Publication of EA200600987A1 publication Critical patent/EA200600987A1/ru
Publication of EA011170B1 publication Critical patent/EA011170B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA200600987A 2003-12-19 2004-12-17 Применение сирамезина в лечении злокачественных опухолей EA011170B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53167003P 2003-12-19 2003-12-19
DKPA200301889 2003-12-19
PCT/DK2004/000885 WO2005058324A1 (en) 2003-12-19 2004-12-17 Use of siramesine in the treatment of cancer

Publications (2)

Publication Number Publication Date
EA200600987A1 EA200600987A1 (ru) 2006-10-27
EA011170B1 true EA011170B1 (ru) 2009-02-27

Family

ID=34702153

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600987A EA011170B1 (ru) 2003-12-19 2004-12-17 Применение сирамезина в лечении злокачественных опухолей

Country Status (8)

Country Link
EP (1) EP1715864A1 (pt)
JP (1) JP2007514666A (pt)
AU (1) AU2004298722A1 (pt)
BR (1) BRPI0416019A (pt)
CA (1) CA2550611A1 (pt)
EA (1) EA011170B1 (pt)
NO (1) NO20063319L (pt)
WO (1) WO2005058324A1 (pt)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013789A1 (en) * 2000-08-15 2002-02-21 H. Lundbeck A/S Pharmaceutical composition containing 1'-[4-[1-(4-fluorophenyl)-1h-indole-3-yl] -1-butyl]-spiro[isobenzofuran-1(3h),4'-piperidine]
EP1224930A1 (en) * 2001-01-22 2002-07-24 Pfizer Products Inc. Combination of a SR inhibitor and sigma receptor ligand in the treatment ofdepression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013789A1 (en) * 2000-08-15 2002-02-21 H. Lundbeck A/S Pharmaceutical composition containing 1'-[4-[1-(4-fluorophenyl)-1h-indole-3-yl] -1-butyl]-spiro[isobenzofuran-1(3h),4'-piperidine]
EP1224930A1 (en) * 2001-01-22 2002-07-24 Pfizer Products Inc. Combination of a SR inhibitor and sigma receptor ligand in the treatment ofdepression

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRENT P.J. ET AL.: "Sigma Binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture" EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 278, no. 2, 1995, pages 151-160, XP002325458 ISSN: 0014-2999 cited in the application abstract page 151, right-hand column, paragraph 1 page 152, left-hand column, paragraph 2 - right-hand column, paragraph 1 page 153, right-hand column, paragraph 2 - page 156, left-hand column, paragraph 2 page 158, right-hand column, paragraph 3 - page 159, left-hand column, paragraph 2 *
CRAWFORD KEITH W. ET AL.: "Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines" CANCER RESEARCH, vol. 62, no. 1, 1 January 2002 (2002-01-01), pages 313-322, XP002325457 ISSN: 0008-5472 cited in the application abstract page 313, right-hand column, last paragraph - page 314, left-hand column, paragraph 1 page 317, left-hand column, paragraph 3 - page 318, left-hand column, paragraph 2 page 320, right-hand column, paragraph 3 - page 321, left-hand column, paragraph 3 *
PERREGAARD JENS ET AL.: "Sigma Ligands with Subnanomolar Affinity and Preference for the omega-2 Binding Site. 1. 3-(omega-Ami noalkyl)-1H-indoles" JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, no. 11, 1995, pages 1998-2008, XP002325456 ISSN: 0022-2623 cited in the application abstract compound 14f tables 1, 2 page 2002, right-hand column, paragraph 2 - page 2003, right-hand column, paragraph 2 page 2006, right-hand column, paragraph 4 *

Also Published As

Publication number Publication date
CA2550611A1 (en) 2005-06-30
EA200600987A1 (ru) 2006-10-27
NO20063319L (no) 2006-07-18
AU2004298722A1 (en) 2005-06-30
JP2007514666A (ja) 2007-06-07
BRPI0416019A (pt) 2007-01-02
WO2005058324A1 (en) 2005-06-30
EP1715864A1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
JP7403950B2 (ja) ヒストンデアセチラーゼ阻害薬及び免疫調節薬の組み合わせ
JPH10245337A (ja) 薬学的組成物
RU2608442C2 (ru) Применение экстрактов лабазника (Filipendula) для лечения и профилактики хронической боли
US20240148694A1 (en) Treatment of androgen deprivation therapy associated symptoms
JP2017511385A (ja) 血液障害の処置に使用するためのｇｌｙｔ１阻害剤
US11285160B2 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
US20090203721A1 (en) Use of siramesine in the treatment of cancer
EA011170B1 (ru) Применение сирамезина в лечении злокачественных опухолей
JP2012520301A (ja) エストロゲン化合物及びその使用方法
CN113521060B (zh) 鱼针草内酯抗新型冠状病毒的用途
WO2021208080A1 (zh) 鱼针草内酯抗新型冠状病毒的用途
US8748475B2 (en) Methods and compositions for treating lupus
MXPA06005132A (en) Use of siramesine in the treatment of cancer
EP0935964A1 (en) Pharmaceutical compositions containing NSAIDs and piperine
RU2675237C1 (ru) Соединение (6-{ [(1S)-1(5-фтор-4-оксо-3-фенил-3,4-дигидрохиназолин-2-ил)пропил]амино} -9Н-пурин-9-ил)метилацетат как ингибитор p110δ - дельта-изоформы фосфоинозитид-3-киназы (PI3K), способы его получения (варианты) и применения
WO2022141328A1 (zh) 硫代咪唑烷酮药物在治疗covid-19疾病中的用途
JP5389471B2 (ja) 鼻閉抑制剤
WO2004039797A1 (fr) Composes d'indole de type special, leur preparation et leur utilisation pour le traitement et la prevention de maladies telles que le cancer
RU2662160C9 (ru) Комбинированный лекарственный препарат для терапии вирусных инфекций
WO2007132280A1 (en) Isatin and its derivatives for use as a medicament
Abortivum Medical Glossary
BR112019011888A2 (pt) Fármaco multialvo para tratar doenças em mamíferos
JPH0769883A (ja) アロマターゼ阻害剤
EA041599B1 (ru) Комбинированный лекарственный препарат для терапии вирусных инфекций
CH678274A5 (en) Appetite suppressing compsn. - includes 5-hydroxy-tryptophan as active component

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU